ENO2 and laryngotracheoesophageal cleft: As shown in Figure 6b–e and Figure S9a–f (Supporting Information), glycosylation‐associated tumor biomarkers like CA15‐3, CA242, CA50, NSE, CA19‐9, and CYRA211 exhibited diminished differences (p  ≤  0.05) in distinguishing the LC group from the control group.